D’Alessio, Silvia
Ungaro, Federica http://orcid.org/0000-0001-5395-7795
Noviello, Daniele http://orcid.org/0000-0002-3482-0109
Lovisa, Sara http://orcid.org/0000-0001-7776-2896
Peyrin-Biroulet, Laurent http://orcid.org/0000-0003-2536-6618
Danese, Silvio http://orcid.org/0000-0001-7341-1351
Article History
Accepted: 27 October 2021
First Online: 7 December 2021
Competing interests
: S.D. declares that she has served as a speaker, consultant, and advisory board member for Abbott (AbbVie), Actelion, Alfa Wasserman, Astra Zeneca, Cellerix, Ferring, Genentech, Grunenthal, Johnson and Johnson, Merck and Co, Millennium Takeda, Novo Nordisk, Nycomed, Pfizer, Pharmacosmos, Schering-Plough, UCB Pharma and Vifor. L.P.-B. declares that he has received personal fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boerhinger Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Hikma, Index Pharmaceuticals, Inotrem, Janssen, Lilly, Merck Sharp & Dohme, Mylan, Nestlé, Norgine, Oppilan, OSE Immunotherapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Theravance, Tillots and Vifor; L.P.-B. also declares that he has received research grants from Abbvie, Merck Sharp & Dohme and Takeda and that he owns stock options in Clinical Trials Mobile Application (CTMA). The other authors declare no competing interests.